LivaNova (NASDAQ:LIVN) Receives Buy Rating from Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They currently have a $75.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 46.14% from the stock’s current price.

Several other equities analysts also recently issued reports on the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group assumed coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, Mizuho reduced their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Trading Down 0.7 %

Shares of LivaNova stock opened at $51.32 on Monday. The firm’s 50 day simple moving average is $52.13 and its two-hundred day simple moving average is $52.45. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 122.19 and a beta of 1.01. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Point72 Asset Management L.P. increased its holdings in LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after buying an additional 863,157 shares in the last quarter. First Light Asset Management LLC increased its holdings in LivaNova by 591.1% in the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after buying an additional 607,598 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in LivaNova in the second quarter valued at $16,614,000. Driehaus Capital Management LLC increased its stake in shares of LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares in the last quarter. Finally, Point72 DIFC Ltd increased its stake in shares of LivaNova by 75,799.6% during the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after purchasing an additional 181,161 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.